Genzyme wins approval for Framingham site

Sanofi's unit Genzyme said on Tuesday it had won U.S. regulatory approval for its Framingham, U.S.-based plant that will produce Fabrazyme, aiming to get patients back on their required dosages of the rare disease drug worldwide this year. A viral contamination at one of Genzyme's plants in 2009 has resulted in shortages of both Fabrazyme, its drug for Fabry disease, and Cerezyme for Gaucher's disease. Source: Reuters 24/1/2012